Haisco licensing deal for two late-stage assets sparks NVCT

 

Haisco licensing deal for two late-stage assets sparks NVCT 22% surge

• Nuvectis announced ex-China rights to NXP100 (Complement Factor B inhibitor for PNH/IgAN/LN) and NXP200 (paradox-breaker BRAF inhibitor for mutated cancers) on June 22.
• Deal includes up to $40M upfront/near-term payments to Haisco, $1.421B potential milestones, and tiered royalties; transforms NVCT into late-stage developer.
• HC Wainwright raised PT to $39 from $13; Lucid Capital to $22 from $18, citing pipeline expansion into multi-billion-dollar markets.
• Stock hit 52-week high near $18.24 with elevated volume; 19.6% gain on June 23 extended into June 24 trading.
• NXP100 has Phase 3/2 data in China; NXP200 shows CNS penetration and responses in BRAF-mutated tumors per release.
• Analysts and retail buzz highlighted best-in-class potential and strategic fit with existing oncology focus.

https://finviz.com/stock?t=NVCT&p=d